הכנסה לפני ניכוי ריבית, מסים ופחת: amarincorp.com (AMRN)

Expanding the distribution network through global partners and engagement with cardiologists is creating strong market momentum for Amarin Corporation plc (AMRN). This chart visualizes this potential via the EBITDA_Co level, where 0.00 determines the current status of the parameter. Growth is driven by the commercialization of Vascepa and cost reductions, although the erosion of patent protection due to US court rulings has paved the way for low-cost generics.

This indicator measures net cash flow from operating activities before deducting depreciation and debt service costs, reflecting the business's actual ability to generate cash amid tight monetary policy. Analyzing the financial EBITDA metric allows for an assessment of cost management efficiency at Amarin Corporation plc (AMRN) during the expansion of Vascepa into European markets and its competition with generic manufacturers.